Annelies de Klein

Annelies de Klein is an Associate Professor in the Department of Clinical Genetics at Erasmus MC, a prominent academic medical center in the Netherlands. She is actively involved in cutting-edge research at the intersection of cancer genetics and developmental genomics.

Research Interests: Her primary research areas include uveal melanoma, metastatic carcinoma, genetic predisposition to congenital anomalies such as diaphragmatic hernia, and epigenetic regulation including DNA methylation. She also investigates circulating tumor DNA and functional consequences of mutations in genes like FOXF1 and ARID1A. Her work combines molecular biology, bioinformatics, and deep learning to uncover disease mechanisms and identify novel therapeutic targets.

Publication Trends: Analysis of her recent publications reveals a strong focus on translational research, particularly in oncology. She employs advanced methodologies such as patient-derived organoids, deep learning for histopathological classification, and genome-wide association studies. Her work spans rare cancers like uveal melanoma and complex developmental disorders, demonstrating a multidisciplinary approach that integrates clinical data with molecular insights.

Scientific Contributions:

• Extensive research output with over 222 publications.
• Active supervision of early-career researchers, with 19 supervised works documented.
• Collaborative research across institutions and disciplines, particularly in genetics and oncology.

Mentorship and Collaboration: Dr. de Klein plays a key role in mentoring graduate students and junior scientists. Her collaborations span clinical and basic research teams, particularly in uveal melanoma (with Kiliç, Brosens, Verdijk) and bladder cancer (with van Leenders, Zuiverloon). She contributes to integrative projects that bridge genomics, pathology, and computational modeling.

Laboratory and Research Environment: She operates within a dynamic research environment in the Clinical Genetics department at Erasmus MC, which supports high-impact translational research in cancer and inherited diseases. Her team leverages state-of-the-art genomic technologies and computational tools to advance precision medicine.